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Conclusions: A regular dose of C increases WR. A second dose consumed shortly after 
produces a smaller but discernible adverse effect on WR adding up to a prolonged total 
effect. This finding has impoltant implications for arterial stiffening and the pulsatile load 
of the heart and may be involved in the pathogenesis of hypertension. 
1133-118 Changes in Lefl Ventricular Structure and Function 
Predict the Onset of Hypertension in Adult 
Normotensives With a Family History of Hypertensive 
Disease: A Seven-Year Follow-Up Study 
Dan Blendea Caius Duncea, Stuarl &rich. Sorin Crisan, Minodora Bedreaga. Roman 
Vlaicu. University of Medicine and Pharmacy, Cluj-Napoca, Romania, Bridgeport 
Hospital, Bridgeport. CT 
Background: Alterations in left ventricular (LV) structure and function have been previ- 
ously shown in normotensive offspring of hypertensive (HT) families but their significance 
is still unclear. 
Methods: To verify if these alterations have predictive value for the onset of HT disease, 
205 norrnotensive adults (mean age 43+/-10 yrs) with family history of HT. were exam- 
ined echocardiographically (2D, M mode, Doppler) at baseline and then repeatedly at 12 
months intewals, during a follow-up period of 7.1 yrs (range 4-7.5 yrs). 
Results: During this period, 57 subjects (26%) became hypertensive (H group). These 
subjects had higher values for the baseline LV mass index (LVMl)(97 +/- 25 g/m2 YS 81 
+/- 21 g/m2: p<O.Ol), lower age adjusted E/A ratios (1.1 +/- 0.4 vs 1.4 +/- 0.4; p<O.OOl). 
and lower LV longitudinal fractional shortening (0.16 +/- 0.03 vs 0.19 +/- 0.03; p=O.O36) 
compared to those who did not develop HT (N group). The subjects in the H group had 
also higher initial systolic blood pressure (SBP) (134 +/- 12 mmHg vs 117 +/- 11 mmHg; 
pcO.01) and a higher number of 1 st degree relatives with HT (2.9 +/- 0.3 vs 1.5 +I- 0.4 ; 
p= 0.044). 
There was no significant difference in baseline LVEF, LV clrcumferentlal fractIonal short- 
ening, LV and diastolic diameter and left atrial size between H and N subjects at base- 
line. 
SBP at the end of the follow-up was predicted independently by the initial SBP 
(beta=0.359; pcO.Ol), age (beta 0.01, p=O.O42) and LVMI (beta=0.165; p<O.Ol). 
During the follow-up period, the subjects who subsequently developed HTN. experienced 
a significant increase in LVMI (from 97+/-25 g/m2 to 104 +/- 26 g/m2; p=O.O39), and 
increase in aortic diameter (from 32 +/- 4 mm to 36 +I- 6 mm; pcO.01). The paired differ- 
ences for all these parameters were significantly higher in the H group compared to the N 
group. H subjects had also higher variations in LV-E/A between the echo exams in the 
follow-up period when compared to the N group (coeff var 25% vs 12%; pcO.01). 
Conclusions: Increased LV mass and alterations in LV diastolic and systolic longitudinal 
function predict the onset of HT in normotensives with family history of HT. Increased 
variability in LV diastolic function seem to appear during the period of developing HT. 
1133-119 N-Terminal Pro-Brain Natriuretic Peptide Predicts 
Cardiovascular Events in Hypertension: A LIFE 
Substudy 
Michael H. Olsen, Kristian Wachtell, Christian Tuxen, Eigil Fossum. Lia E. Bang, 
Christian Hall. Hans Ibsen. Jens Rokkedal. Richard B. Devereux. Per Hildebrandt 
Glostrup University Hospital, Copenhagen, Denmark, Frederiksberg University Hospital, 
Copenhagen, Denmark 
Background: N-terminal pro brain natriuretic peptide (NT-proBNP) is a strong cardio- 
vascular risk factor in patients with chronic heart failure as well as in the general popula- 
tion. We wanted to investigate whether high NT-proBNP could predict the composite 
endpoint (CEP) of cardiovascular death, non-fatal stroke or non-fatal myocardial infarc- 
tion in patients with hypertension and left ventricular hyperlrophy as well. Methods: After 
two weeks of placebo treatment and yearly for 4-5 years clinical, laboratory, and 
echocardiographic variables were assessed in 164 hypertensive patients from the LIFE 
Echo substudy, aged 55-60 (mean 66~7) years. with electrocardiographic LV hypettro- 
phy. NT-proBNP was measured by immunoassay (Elecsys proBNP) at baseline and after 
one year of treatment. 
Results: CEP occurred in 25 patients. Baseline NT-proBNP above the median value of 
165 pg/ml was associated with higher incidence of CEP (16.7% vs 6.7%, P<O.O5). 
Known cardiovascular disease (n=60) defined as diabetes (n=20), or history of either 
ischemic heart disease (n=26), cerebrovascular disease (n=l9), peripheral vascular dis- 
ease (n=5) or chronic heart failure (n=2). was also associated with higher incidence of 
CEP (24.6% vs. 8.9%, P<O.Ol). NT-proBNP above the median value was not associated 
with higher incidence of CEP in this high-risk group (24.3% vs. 21.7%, NS), but was in 
the remaining 124 “low-risk” hypertensive patients (14.6% vs. 4.3%, kO.01). In Cox 
regression analyses controlling for treatment assignment NT-proBNP (PcO.05) predicted 
CEP slightly more strongly than prior cardiovascular disease (kO.054) and current/prior 
smoking (P=O.O6). Systolic blood pressure, gender and body mass index did not enter 
the model. NT-proBNP levels after one year of treatment also tended to predict the CEPs 
that occurred subsequently (18.6% vs. 9.2%, P=O.O7). Conclusion: NT-proBNP is a 
Strong cardiovascular risk factor in patients with hypwtension and LV hypemophy, espe- 
cially in the group without diabetes or clinically overt cardiovascular disease. Further- 
more, our data suggest the possible use of NT-proBNP - even measured dunng 
treatment. as a practical tool for risk stratification in hypertension. 
1133-146 Genetic Analysis of Multiple Risk Factor Syndrome in 
Rats 
Takehiro Watanabe, Yi-Qiang Liang. Hyoe Inomata, Kazuyuki Yanai, Yoko lizuka, 
Takanari Gotoda, Norihiro Kate, International Medical Center of Japan, Tokyo, Japan, 
Tokyo University, Tokyo, Japan 
Background: According to epidemiological studies, cardiovascular risk factors tend to 
cluster in certain individuals, which has been widely recognized as the multiple risk factor 
syndrome. To clarity pathophyslological mechanisms underlying the multiple risk factor 
syndrome, we performed extensive genetic analysis using a unique model organism, the 
spontaneously hypertensive rat (SHR). 
Methods: We undertook genome-wide screens in 2 F2 cohorts independently produced 
from the Wistar-Kyoto rat and SHR of a Japanese colony (151 males in F2-1 and 175 
males in F2-2). In addition to blood pressure. plasma lipid, glucose and insulin levels, 
and body weight, in vitro phenotypes associated with insulin resistance and fat pad 
weight were evaluated in F2-1, while part of F2-2 (n=32) were fed high-fat-high-choles- 
terol (HFHC) diet between 15 and 17 weeks of age. 
Results: In the entire progeny, the most significant linkage to blood pressure was found 
near D3Mitl4 on rat chromosome 3 (maximal LOD score=5.0), where linkage to triglycer- 
ide levels was concomitantly observed. Also, suggestive linkage was observed for blood 
pressure and cholesterol levels on rat chromosome 19. Significant linkage to body weight 
was observed near DZMit5 on rat chromosome 2 (maximal LOD score=4.0 in FZ-2). 
There was a suggestive evidence of linkage to in vitro phenotypes, i.e., glucose uptake 
and lipolysis measured in isolated adipocytes, in a region between D4Mghl7 and 
D4Mghll on rat chromosome 4. far distant from the Cd36 locus. In several chromosomal 
regions, statistical significance of lknkage was enhanced after HFHC diet. 
Conclusion: We have identified the clustering of linkages to more than 1 phenotypic traits 
on a few chromosomes, suggesting the potential existence of genes controllmg multiple 
cardiovascular risk factors at least in rats. Our data also provide a substantial evidence 
for a gene-environment interaction, that is, some quantitative trait loci become prominent 
after a certain dietary intewention. Further investigation including the development of 
congenic strains is currently in progress to resolve these issues. 
1133-147 Cardiovascular Morbidity and Mortality in Hypertensive 
Patients With Atrial Fibrillation: The LIFE Study 
Kristian Wachtell. Bjijrn Horn&am, Mika Lehto, David J. Slotweiner, Eva Gerdts, Peter 
Aurup, Bjijrn DahlW, Hans Ibsen, Steve Julius, Sverre E. Kjeldsen. Markku S. Niemlnen, 
Jens E. Rokkedal, Richard 8. Devereux, Glostrup University Hospital, Glostrup, 
Denmark, The Weill Medical College of Cornell University, New York, NY 
Background: OptImaI treatment of hypertensive patients with atrial fibrillation (AF) to 
reduce the risk of cardiovascular morbidity and mortality remains unclear. 
Methods: As part of the LIFE study, 324 patients (42% women) with AF and hyperten- 
sion (mean age 70+6, pressure 176+14196+10 mmHg) and electrocardiographic left ven- 
tricular (LV) hypertrophy, were assigned to losartan- or atenolol-based therapy for 1,365 
patient-years of follow-up. 
Results: The primary composite endpoint occurred in 36 patients in the losartan-group 
(n=l50) vs. 64 in the atenolol-group (wl74); relative risk (RR) 0.60 [95% Cl 0.40.0.921. 
P=O.O18. Cardiovascular deaths occurred I” 20 vs. 37 patients in the losartan- and 
atenolol-group, respectively: RR 0.58 [Cl 0.34-I ,011, P=O.O53. Stroke occurred in 16 vs. 
37 patients (RR 0.56 [Cl 0.31.0.971, P=O.O40), and myocardlal infarction in 11 vs. 7 
patients (P=NS). There was a trend towards lower all-cause mortality; 30 vs. 46 (RR 0.67 
[Cl 0.43.1.071, P=O.O92), and hospitalization for heart failure took place in 15 vs. 23 
patients (P=NS). Adjustment for blood pressure levels during follow-up had little impact 
on cardiovascular benefit of losartan. 
Conclusion: Los&an was more effective than atenolol-based therapy in reducing the 
risk of the primary composite endpoint of cardiovascular morbidity and mortality as well 
as the secondary endpoints of stroke and cardiovascular death, I” hypertensive patients 
with electrocardiographic LV hypertrophy and AF and there was a trend towards lower 
ail-cause mortality. Hypertensive patients with electrocardiographic LV hypertrophy and 
AF seem to benefit more, for the same blood pressure lowering, from losartan than from 
conventional antihypertensive and antiarrhyihmic treatment by atenolol. 
1133-148 Cardiovascular Safety of Vardenafil in Patients 
Receiving Antihypertensive Medications: A Post-Hoc 
Analysis of Five Placebo-Controlled Clinical Trials 
Robert A. Kloner, Puneet Mohan, Thomas Segerson, Marc Thibonnier, Christ&w 
Norenbarg, Harin Padma-Nathan, Good Samaritan Hospital, Los Angeles, CA, The Male 
Clinic, Beverly Hills, CA 
Background: Hypertension is associated with erectile dysfunction (ED). Phosphodi- 
esterase-5 (PDEd) inhibitors may potent&e blood pressure (BP) reduction of antihyper- 
tensive agents (HTM). This study evaluated the cardiovascular safety of vardenafil, a 
potent, selective PDE-5 inhibitor when used with HTM. 
Methods: Data ware extracted from 5 double-blind Phase Ill trials in which 2,716 men 
with ED received vardenafil 5, 10, or 20 mg or placebo as needed for up to 26 weeks. 
Adverse events and vital signs were tabulated at all visits; in a patient subgroup (n=703), 
vital signs were recorded 11 min to 5 h post-dose. Vardenafil doses were pooled and 
analyzed by HTM use. 
Results: In 2,605 patients valid for safety (vardenafil-1,812, placebo-793), 21 HTM was 
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used by 40%/42% of placebo-lvardenafil-treated patients. The mean change from pre- 
treatment standing SBP/DBP (mmHg). and HR (bpm) in the subgroup having post-dose 
data is summarized below. 
Treatment Placebo Vardenafil 
Group mean (SD) mea” (SD) 
n SBP DBP HR n SBP DBP HR 
All Patients 1 -0.1 -0.02 (10.1) -0.2 5 -4.6 -3.1 (6.5) 2.0 
6 (15.7) (10.4) 2 (13.9) (10.3) 
3 0 
No HTM 9 -1.6 -0.4 (9.4) -0.4 2 -4.2 -2.6 (8.4) 2.0 
3 (15.6) (10.6) 7 (12.2) (10.1) 
1 
21 HTM 9 1.5 0.4 (10.9) 0.1 2 -5.1 -3.7 (6.7) 1.9 
0 (15.7) (10.0) 4 (15.6) (10.5) 
9 
In patients on placebo +I- HTM, no consistent changes in BP and HR were seen. Vard- 
enafil was associated with mild reduction in BP and small increase in HR. Concomiksnt 
HTM minimally incrementally reduced SBPlDBP which were generally similar across 
HTM (ACE-I, Ca+2 antagonist, alpha or beta-blockers. diuretic. or ARB). Incidence of 
angina, arryhythmia, MI or syncope was low and similar irrespective of treatment. 
Conclusion: In this study, concomitant HTM/vardenafil use did not result in vital sign 
changes of clinical concern compared to those observed by vardenafil alone. 
1133-149 Hyperhomocysteinemia Alters Collagen Metabolism in 
the Hypertensive Heart 
Jacob Joseph, Patrick Kennedy, Kerrey Roberto, Abeer Washington. Nawal Shekhawat, 
Lija Joseph, Richard H. Kennedy, University of Arkansas for Medical Sciences, Little 
Rock, AR, Central Arkansas Veterans Healthcare. Little Rock, AR 
We have recently reported the novel association of hyperhomocysteinemia (Hhe) with 
adverse cardiac remodeling in hypertension (Joseph et al, American Journal of Physiol- 
ogy, In Press). Specifically we demonstrated that Hhe increased myocardial collagen Iev- 
els and worsened diastolic function in spontaneously hypertensive rats (SHR). The 
present study was undertaken to further characterize the mechanisms by which Hhe 
altered collagen levels in the SHR model. 
Methods: Left ventricular myocardial tissue homogenates from SHRs given one of three 
diets: control, intermediate Hhe-inducing (IH) or severe Hhe-inducing (SH) were used in 
this study. Western blot analysis was done to analyze collagen I and Ill protein levels. 
Gel zymography was used to assess total gelatinolytic adivity of the left ventricular myo- 
cardium. 
Results: Homocysteine levels (micromolar) after 10 weeks of treatment were control 
4.3+/-0.4; IH -47.1+/&l and SH - 203+/-13. 
We observed an increase in collagen I protein level in the Hhe groups as compared to 
control. The level of collagen Ill decreased in both Hhe groups. increasing the type l/Ill 
collagen ratio as compared to control. Total gelatinolflic activity was also increased in 
both Hhe groups. 
Conclusions: The fibrillar collagens type I and III are major determinants of myocardial 
systolic and diastolic function. Collagen type I has high tensile strength, while type Ill col- 
lagen is much more compliant. The increase in the ratio of type l/Ill collagen with Hhe 
offers a potential explanation for the increased myocardial stiffness and diastolic dys- 
function seen in this model. An increase in total gelatinolytic activity accompanied the 
increase in collagen synthesis, similar to other conditions of fibrosis. In conclusion, 
altered collagen metabolism seems to be an importanr determinant of Hhe-induced 
adverse cardiac remodeling. 
1133-150 Trends in Hypertension-Related Mortality in the United 
States, 1980-l 998 
Carma Ayala, George A. Mensah, Janet B. Croft, Centers for Disease Control and 
Prevention, Atlanta, GA, Cardiovascular Health Branch, Atlanta, GA 
Background: Deaths from heart disease and stroke have declined in past decades; how- 
ever, national trends in hypertension (HTN)- related mortality have not been assessed. 
Methods: National vital statistics multiple cause mortality files from 1960-1996 were ana- 
lyzed for decedents ages 45 years and older with HTN (International Classification of 
Disease code 401-405) listed as one of up to 20 conditions causing death. Racialiethnlc 
comparisons of HTN-related death were assessed ustng age-standardized and age-spe- 
cific rates (per 100,000). 
Results: The number of decedents with HTN increased from 127,294 in 1960 to 216,809 
in 1996. Overall, the age-standardized rate increased from 265.7 in 1960 to 361.2 in 
1998 which was a relative increase of 33% (95% Cl=3%-64%). Age-standardized death 
rates from 1960 to 1996 were consistently highest among black men. followed (in 
descending order) by black women, white men, and white women. From 1960 to 1996, 
age-specific death rates for HTN-related mortality increased 175% (95% Cl=20%-246%) 
for ages 65 years and older, 28% (95% Cl=4%-55%) for ages 75.84 years, and 6% (95% 
CI=2%-15%) for ages 65-74 years but decreased -6% (95% Cl=-2%. -12%) for ages 45- 
64 years. 
COnclusiOn: HTN-related mortality has increased in the US over the last two decades, 
especially for adults aged 65 years and older. Because the residual lifetime risk for HTN 
among middle-aged and elderly adults is high, this trend is lkkely to continue as the popu- 
lation ages. Prevention of HTN must continue to be pursued and recognized as a strat- 
egy to reduce cardiovascular disease morbidity and mortality, especially among black 
adults. These results also reflect delayed ages for HTN-related mortality. Reductions in 
HTN-related mortality for adults under age 65 years may have been influenced by 
national improvements in detection and use of management strategies during the past 
two decades. 
1133-151 Left Ventricular Mechanics and Tissue Characterization 
in Hypertensive Children: What Are the Earlier Markers 
of Heart Damage? 
Giusepue Pacileq Marina Verrengia, Giuseppe Limongelli, Giuliana Lama, Mtchele 
Tedesco, Giovanni Di Salvo, Giovanna M. Russo, Raffaele Calabr& Second University, 
A.O. Monaldi Hospital, Naples, Italy 
Background : Early LV functional abnormalities of hypertension in paediarric age has 
not been extensively investigated. Thus. we non-invasively assessed LV mechanics and 
tissue characterization in hypertensive children 
Methods: 21 untreated pts (aged 12.1*6 yrs ) with renal disease and a recent diagnosis 
(-z 6 months) of hypettension at ambulatory blood pressure monitoring underwent an 
echocardiographic evaluation. Sex- and age-specific cutoff levels for LV mass/heigh+’ 
and relative wall thickness were defined to assess LV geometry, as normal, concentric 
remodeling(CR), concentric hypertrophy(CH), eccentric hypertrophy(EH). As load-inde- 
pendent index of myocardial contractility, the relation between the midwall rate-corrected 
velocity of circumferential fiber shortening and meridional end-systolic stress (mwVCFc- 
s..) was defined. LV diastolic function was evaluated by the mitral flow Indexes (peak E, 
peak A, E/A ratio, deceleration time) and isovolumic relaxation time. Finally. ultrasonic 
tissue characterization of the LV myocardium was performed by integrated backscatter. 
In addition, 35 age- and BSA-matched normal subjects were used as control group. 
Results: LV geometry was abnormal in 5/21 pts (2 CR, 1 CH. 2 EH) (23%). LVMl 
heigh?,? which significantly correlated with mean 24-hours systolic pressure 
(r=0.46;p>0.05) was >51 g/m”’ in 2/21 (9.5%) pts. The mwVCFcs,, relation was nor- 
mal (M+PSD) in all pts. lsovolumic relaxation time was prolonged in 12/21(57%) pts and 
deceleration time in 1 I/21 (52%) pts: peak A was increased in 14/21 (66%) and WA ratio 
was decreased in 12/21 (57%) pis. Finally, compared lo control group, Integrated back- 
scatter analysis did not show significant differences in hypertenswe children. 
Conclusions: Majority of hypertensive children show early abnormal LV filling, sugges- 
tive of impaired diastolic relaxation. Significantly, abnormal LV geometry was detected in 
23% and LVM/height2’ was > 51 s/m *.’ in 9.5% of pts. Thus, an early echocardiogrphic 
evaluation of LV diastolic function and geometry allows us to identify a subset of hyper- 
tensive children with heart damage and increased risk of cardiovascular morbility 
1133-152 Diastolic Function in Obese Children Assessed by 
Tissue Doppler Imaging 
Hollv M. Ippisch, Will L. Border, Sandra A. Witt, Betty J. Glascock, Phil R. Khowy, 
Thomas R. Kimball, Cincinnati Children’s Hospital, Cincinnati, OH 
Background: Our previous studies show that obese children have enhanced LV systolic 
performance and LV hypertrophy. Using traditional mitral inflow indices, diastolic dys- 
function has not been apparent. Tissue Doppler imaging (TDI) indices may be more sen- 
sitive for detecting diastolic dysfunction. Our aim was to compare TDI indices in obese 
versus normal children, and to determine correlates of these indices. 
Methods: 146 obese children had echocardiograms. Diastolic function was assessed by 
TDI indices. TDI indices included the early and late peaks of mitral annular velocity at the 
septum (E-sep, A-sep) and lateral (E&t. A-lat) walls. LV mass, body mass index, and 
blood pressure were measured. These data were compared to normal controls. 
Results: The TDI indices for E waves (E-sep, E-lat) were lower than controls, and the 
Indices for A waves (A-sep, A-lat) were higher than controls (Figure). 
.___~~_ -,lll~“*-~x.s_._ 
LV mass correlated with A-lat (r=-0.18, p=O.O3). Systolic blood pressure correli 
A-sep (rc0.19, p=O.O2). There was no correlation with body mass index 
ed with 
COnclusfon:TDI indices were significantly different in obese children. These newer indi- 
ces of diastolic function, may provide a method for serial monitoring for cardiovascular 
disease. Identification of these children could allow for earlier initiation of interventional 
strategies aimed at reducing cardiovascular risk. 
